XLO stock forecast, quote, news & analysis
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer... Show more
Why Xilio Therapeutics (XLO) Stock Is Down -11.5% in the Last 30 Days
Key Takeaways
- Xilio Therapeutics (XLO) fell roughly 11.5% over the 30 days through late October 2026, declining from about $9.05 to approximately $8.01.
- The decline was concentrated in the second half of October, punctuated by a Weiss Ratings downgrade to a "Sell" rating on October 23, 2026.
- Over the last quarter, the stock traded mostly range-bound between about $8.80 and $9.50 before the recent sell-off, leaving it broadly lower for the period.
- Xilio is a clinical-stage biotechnology company developing masked immuno-oncology therapies, supported by collaboration and license agreements with AbbVie (ABBV) and Gilead Sciences (GILD).
- The company reported second-quarter 2026 results that exceeded consensus estimates and held roughly $136 million in cash with an anticipated runway into early 2028.
- For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- To discover AI-driven trading strategies across thousands of tickers, visit Trending AI Robots.
Xilio Therapeutics (XLO) Company Overview and Market Position
Xilio Therapeutics is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on discovering and developing masked immuno-oncology (I-O) therapies. Its proprietary masking technology is designed to keep therapeutic agents inactive in healthy tissue and selectively activate them within the tumor microenvironment, aiming to deliver durable efficacy while reducing the systemic side effects often associated with conventional cancer immunotherapies.
The company's pipeline includes XTX501, a bispecific PD-1/masked IL-2 candidate being evaluated in metastatic non-small cell lung cancer and select advanced solid tumors; efarindodekin alfa, a masked IL-12 in a Phase 2 trial; and vilastobart, a tumor-activated anti-CTLA-4 antibody. Xilio has also advanced masked T cell engager programs targeting antigens such as CLDN18.2, PSMA, and STEAP1. Strategic collaborations with AbbVie and Gilead Sciences provide non-dilutive funding and validation of the platform, which is a key reason investors follow the stock.
Xilio Therapeutics (XLO) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 days ending in late October 2026, XLO shares declined approximately 11.5%, moving from a closing price of about $9.05 to roughly $8.01. The move was not linear: the stock held near the $9.00 level through most of September and early October before selling off sharply beginning in mid-October. The stock closed as low as $7.31 on October 26 before rebounding to about $8.01 in the following session.
The quarterly picture tells a similar but more measured story. For much of the prior three months, XLO traded in a relatively narrow band between roughly $8.80 and $9.50, reflecting limited near-term catalysts and generally light trading volume. Because most of the downside occurred in the final weeks of the period, the quarterly decline is largely a reflection of the recent 30-day move rather than a steady multi-month downtrend.
What Drove XLO Stock Price in the Last 30 Days
The most concrete catalyst behind the late-October decline was a ratings action. On October 23, 2026, Weiss Ratings downgraded Xilio Therapeutics to a "Sell" rating, and the stock fell approximately 5.7% that session. The move came amid a period of thin trading volume, which can amplify price swings in a small-cap, clinical-stage name with a relatively modest float.
Broader sentiment also played a role. Small-cap biotechnology stocks remain sensitive to shifts in risk appetite, and XLO's low average daily volume makes it prone to outsized moves on comparatively modest selling pressure. The decline occurred despite second-quarter 2026 results reported in August that beat consensus estimates, with a narrower-than-expected net loss and collaboration revenue above analyst projections, suggesting the recent pressure was driven more by sentiment and rating dynamics than by a deterioration in fundamentals.
What Drove XLO Stock Performance Over the Last Quarter
Across the broader quarter, XLO traded in a sideways range as investors weighed the company's pipeline progress against its early-stage, pre-revenue status. The period was framed by execution milestones announced earlier in 2026, including a 1-for-14 reverse stock split completed in March 2026, an IND filing for XTX501 planned for mid-2026, and continued progress across its masked T cell engager programs.
Fundamentally, Xilio's financial position remained stable through the quarter. The company reported about $136 million in cash and cash equivalents as of June 30, 2026, and extended its anticipated cash runway into the first quarter of 2028. Collaboration revenue tied to the AbbVie and Gilead agreements continued to grow year over year. Against this backdrop, the stock's late-quarter decline appears more reflective of short-term rating and sentiment pressure than any single fundamental setback.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a broader ecosystem of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant bots are featured in this section, making it a useful starting point for traders seeking algorithmic strategies. The bots span a variety of approaches, timeframes, and performance metrics, so investors can compare strategies that range from short-term momentum to longer-horizon positioning. Exploring the page can help traders identify automated tools aligned with their own risk tolerance and objectives.
XLO Stock Forecast Drivers: What Investors Should Watch Next
Investors tracking XLO should monitor several near-term catalysts. The company's next quarterly earnings report is a key checkpoint for collaboration revenue, expense trends, and updated cash-runway guidance. Progress on the XTX501 program—including the planned mid-2026 IND submission and subsequent clinical enrollment—represents a central driver of pipeline value.
Additionally, milestone and option-related developments under the AbbVie and Gilead agreements, including the anticipated delivery of a Phase 1/2 option data package for efarindodekin alfa to Gilead in the first half of 2027, could influence sentiment. Broader factors such as biotech sector risk appetite, small-cap liquidity, and any further analyst ratings changes also merit attention, given the stock's sensitivity to these dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XLO's Stochastic Oscillator sits in overbought zone for 5 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
XLO moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for XLO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XLO's RSI Oscillator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on XLO as a result. In 76 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for XLO just turned positive on November 03, 2026. Looking at past instances where XLO's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLO advanced for three days, in 158 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
XLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.799) is normal, around the industry mean (3.498). P/E Ratio (-27.406) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. XLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology